VentriPoint Diagnostics (CVE:VPT) Shares Down 8.7% – Should You Sell?

Shares of VentriPoint Diagnostics Ltd. (CVE:VPT) fell 8.7% on Tuesday . The company traded as low as C$0.09 and last traded at C$0.11. 288,748 shares changed hands during trading, an increase of 140% from the average session volume of 120,081 shares. The stock had previously closed at C$0.12.

VentriPoint Diagnostics Stock Down 4.5%

The company has a debt-to-equity ratio of -58.56, a current ratio of 0.28 and a quick ratio of 6.67. The company has a market cap of C$18.06 million, a PE ratio of -3.50 and a beta of -0.60. The business’s 50 day moving average is C$0.12 and its 200-day moving average is C$0.11.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.